US3755581036 - Common Stock
GILEAD SCIENCES INC
NASDAQ:GILD (4/17/2024, 7:01:44 PM)
Premarket: 67.03 +0.1 (+0.15%)66.93
-0.38 (-0.56%)
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The firm offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The firm's other products include AmBisome and Letairis. The company also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA 94404
P: 16505743000
CEO: Daniel P. O'Day
Employees: 17000
Website: https://www.gilead.com/
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
Dividend stocks can be a smart way to ride out market volatility.
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
Here you can normally see the latest stock twits on GILD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: